Closed for Enrollment

• A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy (OPUS) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure frequency.

• Usage of EpiFinder Clinical Decision Support in the Assessment of Epilepsy Cases at Mayo Clinic Hospital in AZ Scottsdale/Phoenix, Ariz.

  Clinical decision support in neurology will be using the EpiFinder tool during the assessment of patients who are being evaluated for possible epileptic seizures and syndromes.  A formal knowledge representation has been created that incorporates existing accepted classifications and peer-reviewed papers in the domain from the International League Against Epilepsy.  A heuristic algorithm has been developed that uses the knowledge representation in an algorithm that attempts to guide the assessment and provide a differential diagnosis of specific epilepsy syndromes encountered at Mayo Clinic Hospital’s Epilepsy Monitoring Unit in Arizona.  The aim is to improve the knowledge representation, term usage, assessment process, and differential based on feedback from usage.